Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24711532 | 1.00 | PDCD1LG2 (0.41) | PDCD1LG2CD274EPHX2DRD2AKR1C3 | |
| SCHEMBL17722618 | 1.00 | PDCD1LG2 (0.41) | PDCD1LG2CD274EPHX2DRD2AKR1C3 | |
| SCHEMBL21739329 | 0.90 | TDP1 (0.38) | PDCD1LG2CD274DRD2KDM5A | |
| SCHEMBL22052769 | 0.90 | TDP1 (0.38) | PDCD1LG2CD274DRD2KDM5A | |
| SCHEMBL21739497 | 0.90 | TDP1 (0.38) | PDCD1LG2CD274DRD2KDM5A | |
| SCHEMBL9819607 | 0.81 | NLRP3 (0.41) | PDCD1LG2CD274KDM5A | |
| SCHEMBL18032523 | 0.81 | LTA4H (0.40) | KDM5A | |
| SCHEMBL17718802 | 0.81 | PDCD1LG2 (0.39) | PDCD1LG2CD274EPHX2DRD2DRD3 | |
| SCHEMBL25664016 | 0.81 | PIK3CD (0.44) | PDCD1LG2CD274EPHX2DRD2KDM5A | |
| SCHEMBL25666931 | 0.81 | PDCD1LG2 (0.38) | PDCD1LG2CD274EPHX2DRD2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | PDCD1LG2 4245/4885CD274 4759/4885EPHX2 2137/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | PDCD1LG2 866/4885CD274 2620/4885EPHX2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.